Immix Biopharma CFO granted 500,000 stock options

Immix Biopharma, Inc. reported that its CFO and President, Morris Gabriel S, received a grant of stock options covering 500,000 shares of Common Stock.

Rhea-AI Filing Summary

Immix Biopharma, Inc. reported that its CFO and President, Morris Gabriel S, received a grant of stock options covering 500,000 shares of Common Stock. The options have an exercise price of $8.78 per share and expire on May 22, 2036. The award vests in 48 equal monthly installments after the grant date, tying the executive’s potential ownership to continued service with the company.

Insights

Equity compensation analyst

Routine executive stock option grant with long-term vesting.

Morris Gabriel S, CFO and President of Immix Biopharma, received a stock option grant for 500,000 underlying Common Stock shares at an exercise price of $8.78 per share. The options expire on May 22, 2036, indicating a long-dated incentive.

The filing states that the option vests in 48 equal monthly installments following the grant date, conditioned on continued service. This structure aligns the executive’s potential equity gains with sustained tenure and performance, and there are no same-day sales or exercises reported in this filing.

Insider Trade Summary

Grant/Award: 500,000 shares

Grant/Award 1 txn

Insider Morris Gabriel S

Role CFO, President

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	500,000	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 500,000 contracts (Direct)

Footnotes (1)

1. F1. The Stock Option will vest in 48 equal monthly installments following the date of grant, subject to the Reporting Person's continued service with the Issuer.

Key Figures

Option grant size: 500,000 shares Exercise price: $8.78 per share Expiration date: May 22, 2036 +2 more

5 metrics

Option grant size 500,000 shares Underlying Common Stock in new stock option award

Exercise price $8.78 per share Conversion or exercise price of stock option

Expiration date May 22, 2036 Stock option expiration

Vesting schedule 48 monthly installments Vesting following the grant date, service-based

Options held after grant 500,000 options Total derivative securities following this transaction

Key Terms

Stock Option (Right to Buy), exercise price, vest in 48 equal monthly installments, derivative securities, +1 more

5 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

exercise price financial

"conversion_or_exercise_price: 8.7800"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vest in 48 equal monthly installments financial

"The Stock Option will vest in 48 equal monthly installments"

derivative securities financial

"derivativeTransactionCount: 1 for this derivative-type record"

Financial contracts whose value is tied to the price or performance of another asset, such as a stock, bond, commodity, index, or currency; examples include options, futures and swaps. They matter to investors because they let you protect against price swings, bet on future moves or gain larger exposure with less upfront cash—like using a lever or insurance policy on an investment—so they can amplify gains and losses and help manage portfolio risk.

Grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Immix Biopharma (IMMX) disclose about Morris Gabriel S in this Form 4?

Immix Biopharma reported that CFO and President Morris Gabriel S received a stock option grant for 500,000 shares of Common Stock. The options were awarded at an exercise price of $8.78 per share and represent equity-based executive compensation, not a public market trade.

How many shares are covered by the new stock option grant to Immix Biopharma’s CFO?

The stock option grant to Immix Biopharma’s CFO covers 500,000 underlying Common Stock shares. This entire amount was acquired in a single award transaction coded as a grant, increasing his derivative holdings linked to the company’s equity compensation program.

What is the exercise price and expiration date of the Immix Biopharma CFO’s stock options?

The granted stock options have an exercise price of $8.78 per share and an expiration date of May 22, 2036. These terms define the cost to purchase shares in the future and the final date on which the options can be exercised.

How do the Immix Biopharma CFO’s new stock options vest over time?

The stock option award vests in 48 equal monthly installments following the grant date. Vesting is conditioned on the reporting person’s continued service with Immix Biopharma, gradually delivering exercisable options over four years instead of all at once.

Did the Immix Biopharma Form 4 show any stock sales or market purchases by the CFO?

The Form 4 shows a grant/award acquisition of stock options but no open-market purchases or sales. The transaction code is “A,” indicating an award of derivative securities as compensation rather than a buy or sell transaction in the company’s common stock.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/29/2026 - 05:05 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Morris Gabriel S

(Last) (First) (Middle)

C/O IMMIX BIOPHARMA, INC.

11400 WEST OLYMPIC BLVD., SUITE 200

(Street)

LOS ANGELES CALIFORNIA 90064

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Immix Biopharma, Inc. [ IMMX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CFO, President

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/22/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$8.78	05/22/2026		A		500,000		(1)	05/22/2036	Common Stock	500,000	$0	500,000	D

Explanation of Responses:

1. The Stock Option will vest in 48 equal monthly installments following the date of grant, subject to the Reporting Person's continued service with the Issuer.

	/s/ Gabriel S. Morris	05/29/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)